xRead - September 2022

Wise et al.

Page 184

30. Todo-Bom A, Loureiro C, Almeida MM, et al. Epidemiology of rhinitis in Portugal: evaluation of the intermittent and the persistent types. Allergy. 2007;62:1038–1043. [PubMed: 17686106] 31. Demoly P, Passalacqua G, Pfaar O, Sastre J, Wahn U. Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. Allergy Asthma Clin Immunol. 2016;12:2. [PubMed: 26759555] 32. Zuberbier T, Bachert C, Bousquet PJ, et al. GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65:1525–1530. [PubMed: 21039596] 33. Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854–867. [PubMed: 24761804] 34. Haahtela T, Burbach GJ, Bachert C, et al. Clinical relevance is associated with allergen-specific wheal size in skin prick testing. Clin Exp Allergy. 2014;44:407–416. [PubMed: 24283409] 35. Varghese M, Glaum MC, Lockey RF. Drug-induced rhinitis. Clin Exp Allergy. 2010;40:381–384. [PubMed: 20210811] 36. Settipane RA, Kaliner MA. Chapter 14: Nonallergic rhinitis. Am J Rhinol Allergy. 2013;27 Suppl 1:S48–51. 37. Walgama ES, Hwang PH. Aspirin-exacerbated respiratory disease. Otolaryngol Clin North Am. 2017;50:83–94. [PubMed: 27888917] 38. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med. 2002;347:1493– 1499. [PubMed: 12421891] 39. Barnes PJ. Neurogenic inflammation in the airways. Respir Physiol. 2001;125:145–154. [PubMed: 11240158] 40. Kaliner MA, Baraniuk JN, Benninger M, et al. Consensus definition of nonallergic rhinopathy, previously referred to as vasomotor rhinitis, nonallergic rhinitis, and/or idiopathic rhinitis. World Allergy Organ J. 2009;2:119–120. [PubMed: 24229320] 41. Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23–34. [PubMed: 17153005] 42. Mah GT, Tejani AM, Musini VM. Methyldopa for primary hypertension. Cochrane Database Syst Rev. 2009:CD003893. 43. Kiroglu AF, Bayrakli H, Yuca K, Cankaya H, Kiris M. Nasal obstruction as a common side-effect of sildenafil citrate. Tohoku J Exp Med. 2006;208:251–254. [PubMed: 16498233] 44. Motamed M, Sandhu D, Murty GE. Sildenafil and nasal obstruction. J Otolaryngol. 2003;32:259– 261. [PubMed: 14587568] 45. Cingi C, Ozdoganoglu T, Songu M. Nasal obstruction as a drug side effect. Ther Adv Respir Dis. 2011;5:175–182. [PubMed: 21511676] 46. Togias A Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol. 2000;105:S599– 604. [PubMed: 10856164] 47. Riccio MM, Proud D. Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol. 1996;97:1252–1263. [PubMed: 8648021] 48. Shirasaki H, Kanaizumi E, Himi T. Immunohistochemical localization of the bradykinin B1 and B2 receptors in human nasal mucosa. Mediators Inflamm. 2009;2009:102406. [PubMed: 19404481] 49. Trimarchi M, Miluzio A, Nicolai P, Morassi ML, Bussi M, Marchisio PC. Massive apoptosis erodes nasal mucosa of cocaine abusers. Am J Rhinol. 2006;20:160–164. [PubMed: 16686379] 50. Tan TH, Stevenson B, Yip D. Docetaxel-induced nasal septal perforation. Intern Med J. 2006;36:471–472. [PubMed: 16780459] 51. Lanier B, Kai G, Marple B, Wall GM. Pathophysiology and progression of nasal septal perforation. Ann Allergy Asthma Immunol. 2007;99:473–479; quiz 480-471, 521. [PubMed: 18219827] 52. Wang SH, Wang HW, Wang JY. Effects of cocaine on human nasal mucosa. Eur Arch Otorhinolaryngol. 1993;250:245–248. [PubMed: 8369121]

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.